Currently Viewing:
American Society of Hematology Annual Meeting & Exposition
Research to Look Out for at ASH 2018
November 26, 2018
Real-World Evidence With Axicabtagene Ciloleucel CAR T Treatment Similar to ZUMA-1 Trial Findings
December 01, 2018
Studies at ASH Evaluate Episodic ED Utilization, Adherence, QOL in Sickle Cell Disease
December 01, 2018
Currently Reading
Dr Theresa Keegan: AYAs Continue to Be Underrepresented in Clinical Trials
December 01, 2018
Length of Hospital Stay Key Driver of Costs Associated With CRS Following CAR T Treatment
December 02, 2018
Dr Jeff Sharman Discusses Standard of Care for CLL Based on Treatment Setting
December 03, 2018
Dr Alison Moskowitz on the Importance of Patients Understanding Their Diagnosis, Treatment Options
December 03, 2018
Ibrutinib Alone Better Than Chemoimmunotherapy as Frontline in Older Patients With CLL
December 03, 2018
ASH-EHA Joint Symposium Dives Deep Into the Leukemia–Down Syndrome Connection
December 03, 2018
iLLUMINATE: Superior PFS With Ibrutinib–Obinutuzumab Even in High-Risk, Untreated CLL/SLL
December 03, 2018
Dr Irene Roberts on Increased Risk of Leukemia in Patients With Down Syndrome
December 03, 2018
Dr Robert Rifkin Outlines Recent Treatment Advances in Multiple Myeloma
December 03, 2018
NCI Director Highlights a Year of Progress in Hematology, Outlines Areas of Focus Going Forward
December 18, 2018
Dr Jeff Sharman: Cost of Therapy Is a Major Challenge in CLL
January 06, 2019
Dr Theresa Keegan on Barriers, Facilitators to Clinical Trial Participation Among AYAs
January 07, 2019
Dr Jennifer Brown on the Role of Genomic Sequencing in CLL
January 08, 2019
Dr Robert Rifkin Discusses Barriers, Biomarkers in Multiple Myeloma
January 10, 2019
Dr Robert Rifkin on Lack of Education Surrounding Biosimilars
January 22, 2019

Dr Theresa Keegan: AYAs Continue to Be Underrepresented in Clinical Trials

There have been substantial efforts to increase both access to and participation in clinical trials among adolescents and young adults (AYAs), but their representation remains low, explained Theresa H.M Keegan, PhD, MS, associate professor, hematology and oncology, University of California at Davis Comprehensive Cancer Center. 


There have been substantial efforts to increase both access to and participation in clinical trials among adolescents and young adults (AYAs), but their representation remains low, explained Theresa H.M. Keegan, PhD, MS, associate professor, hematology and oncology, University of California at Davis Comprehensive Cancer Center. 

Transcript

How represented are adolescents and young adults in clinical trials?

Overall, AYAs, which are adolescents and young adults, and we typically define that as 15-39 years of age, are less represented in clinical trials than children. So, back in 2006, we reported that 14% of AYAs participated in clinical trials. This was using population-based data in the surveillance, epidemiology, and end results program. This is in contrast to children, where approximately 90% are treated at institutions with NCI-sponsored clinical trials, and as many as two-thirds participating in clinical trials. So, there’s pretty dramatic differences by age in terms of clinical trial participation.

Has representation changed over recent years?

So, not really, actually. Part of our goal in our education session was to look at changes over time. There’s been substantial efforts to increase both access to and participation for AYAs in clinical trials, and this is really because we’ve noticed less improvement in AYAs in survival over the past 30 years, and this has been attributed to lower participation in clinical trials, as well as a number of other factors.

So, our goal was to look to see if we have seen an increase in participation over time. We were able to do some work ourselves in population-based data and found that in 2012 and 2013, we saw a modest increase from 15% to 18%, and these were in acute lymphoblastic leukemia (ALL), Hodgkin, non-Hodgkin lymphoma patients and sarcoma patients. But really no significant increases over time.

There was a suggestion that there is an increased participation in ALL trials, and this has been noted by others. So, that may be the one exception--that for those patients, that there is some increase in trial accrual, and there has been a lot of attention given to adolescent and young adult ALL patients. But again, overall and in general, we don’t see increased clinical trial participation.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up